Not Yet RecruitingPhase 2

Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)

United States25 participantsStarted 2026-06

Plain-language summary

The purpose of this clinical trial it to test the safety and tolerability of the study drugs mosunetuzumab in combination with pirtobrutinib in patients with relapsed or refractory Waldenstrom's Macroglobulinemia.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓-≥ 50 years of age:

Exclusion criteria

✕--Left ventricular ejection fraction \< 40% within 12 months prior to first dose of study therapy.
✕-Note: Participants with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \[anti-HBc\] and absence of HBsAg) are eligible. Participants with positive anti-HBc and negative HBV DNA should be on prophylactic nucleo(t)side analogue therapy to prevent reactivation with serial HBV DNA PCR monitoring Participants positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.

What they're measuring

The recommended phase 2 dose (RP2D) which will be determined based on the rate of dose-limiting toxicities (DLTs) during the DLT evaluation period.

Timeframe: 5 years

Best very good partial response (VGPR) or better per the modified IWWM6 criteria.1

Timeframe: 5 years

Trial details

NCT IDNCT07548450

SponsorUniversity of Utah

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2034-06

Contact for this trial

David Samuel

8015874713 david.samuel@hci.utah.edu

View on ClinicalTrials.gov More Waldenstrom Macroglobulinemia trials